Hanstone Gold (OTC:HANCF) Stock, Quote.Headers.trade-ideas

Hanstone Gold Corp is a mineral exploration company focused on the exploration of its Doc Property located in the Skeena Mining Division in British Columbia. Its project includes Doc and Snip North.

HANSTONE GOLD CORP by HANSTONE GOLD CORP.

Hanstone Gold Corp

Financial giants have made a conspicuous bullish move on Deere. Our analysis of options history for Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) revealed 32 unusual trades.
Delving into the details, we found 56% of traders were bullish, while 34% showed bearish tendencies. Out of all the trades we spotted, 29 were puts, with a value of $1,287,729, and 3 were calls, valued at $706,047.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $380.0 and $430.0 for Deere, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Deere options trades today is 251.36 with a total volume of 3,334.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Deere's big money trades within a strike price range of $380.0 to $430.0 over the last 30 days.
<h3>Deere Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726850889_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$21.3</td>
<td>$20.35</td>
<td>$21.25</td>
<td>$430.00</td>
<td>$637.5K</td>
<td style="text-align: right;">401</td>
<td style="text-align: right;">305</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$6.6</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$400.00</td>
<td>$181.5K</td>
<td style="text-align: right;">215</td>
<td style="text-align: right;">540</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$4.3</td>
<td>$4.0</td>
<td>$4.05</td>
<td>$390.00</td>
<td>$82.2K</td>
<td style="text-align: right;">729</td>
<td style="text-align: right;">322</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$38.75</td>
<td>$37.65</td>
<td>$38.2</td>
<td>$400.00</td>
<td>$76.4K</td>
<td style="text-align: right;">117</td>
<td style="text-align: right;">101</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$38.65</td>
<td>$38.0</td>
<td>$38.0</td>
<td>$400.00</td>
<td>$76.0K</td>
<td style="text-align: right;">117</td>
<td style="text-align: right;">121</td>
</tr>
</tbody>
</table>

<h3>About Deere</h3>
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
<h3>Where Is Deere Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 585,017, the DE's price is down by -0.4%, now at $408.1. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 61 days.</li>
</ul>
<h3>What The Experts Say On Deere</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $425.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Deere, maintaining a target price of $425. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Deere with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Deere's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bullish stance on Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TSM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 34 uncommon options trades for Taiwan Semiconductor.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 41%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $868,205, and 23 are calls, for a total amount of $2,542,785.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $200.0 for Taiwan Semiconductor over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Taiwan Semiconductor's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Taiwan Semiconductor's whale trades within a strike price range from $120.0 to $200.0 in the last 30 days. 
<h3>Taiwan Semiconductor 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726850884_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$22.3</td>
<td>$22.25</td>
<td>$22.25</td>
<td>$190.00</td>
<td>$712.0K</td>
<td>477</td>
<td>1.3K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.4</td>
<td>$190.00</td>
<td>$378.0K</td>
<td>12.2K</td>
<td>2.6K</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.71</td>
<td>$2.7</td>
<td>$2.7</td>
<td>$160.00</td>
<td>$319.9K</td>
<td>11.6K</td>
<td>2.1K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$57.05</td>
<td>$54.05</td>
<td>$57.05</td>
<td>$120.00</td>
<td>$285.2K</td>
<td>590</td>
<td>0</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$9.95</td>
<td>$9.9</td>
<td>$9.95</td>
<td>$180.00</td>
<td>$177.1K</td>
<td>8.4K</td>
<td>1.1K</td>
</tr>
</tbody>
</table>

<h3>About Taiwan Semiconductor</h3>
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with over 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.
<h3>Present Market Standing of Taiwan Semiconductor</h3>
<ul>
<li>Trading volume stands at 5,267,160, with TSM's price down by -0.23%, positioned at $175.82.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Taiwan Semiconductor with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Taiwan Semiconductor Unusual Options Activity For September 20

Analog Devices (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adi#NASDAQ">ADI</a>) recently announced its strategic alliance with Tata Group to advance the semiconductor ecosystem in India and leverage its products in Tata applications like electric vehicles and network infrastructure.
This collaboration is expected to be mutually beneficial and is a significant step in establishing a robust electronics manufacturing ecosystem in India for domestic and global consumption.
Tata Electronics, Tata Motors and Tejas Networks signed a Memorandum of Understanding with ADI to enhance strategic and business cooperation and explore opportunities for semiconductor manufacturing in India.
<h2>Strategic Partnerships to Boost ADI&#39;s Prospects</h2>
ADI&#39;s recent collaboration with Honeywell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hon#NASDAQ">HON</a>) to digitize commercial spaces without replacing existing wiring, reducing costs and downtime is a noteworthy development.
Analog Devices announced a strategic partnership with Flagship Pioneering to speed up the development of a fully digitized biological world.&nbsp;
<div class="chart_embed">
<h3>Analog Devices, Inc. Price and Consensus</h3>
<img alt="Analog Devices, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/ed/1726758783.png" style="height:265px; width:620px" title="" />
Analog Devices, Inc. price-consensus-chart | Analog Devices, Inc. Quote
It teamed up with Taiwan Semiconductor (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>) to secure long-term wafer capacity via Japan Advanced Semiconductor Manufacturing. This partnership, while ensuring a stable chip supply and facilitating rapid scaling and increased output to meet customer needs can be a game changer for ADI.
ADI&#39;s partnership with SambaNova Systems to rapidly deploy their enterprise-scale generative AI platform for enabling customer success might be a plus.
</div>
<h2>Analog Devices Suffers From Stiff Competition</h2>
Despite having a strong partner base, macroeconomic challenges remain a concern. Geo-political tensions and recessionary fears are major negatives.
ADI faces stiff competition from players like Texas Instruments (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txn#NASDAQ">TXN</a>), which is also making efforts to integrate generative AI capabilities into its products.
On a year-to-date basis, ADI has underperformed TXN, which gained 17.7%.
ADI shares have plunged 12.1% year to date against the broader Zacks Computer and Technology sector&#39;s return of 19.4%.
In the first half of fiscal 2024, ADI reported revenues of $4.67 billion, down 36% from the year-ago period. This underperformance can be firmly pointed toward the softness in the industrial, communications and automotive end markets.
<h2>ADI&#39;s Q4 Guidance Positive</h2>
For fourth-quarter fiscal 2024, ADI expects revenues of $2.40 billion (+/- $100 million), up 4% sequentially at the midpoint. The Zacks Consensus Estimate for the same is pegged at $2.41 billion, indicating a fall of 11.4% year over year.
ADI anticipates a non-GAAP operating margin of 41% (+/- 100 bps).
The company expects non-GAAP earnings to be $1.63 (+/- $0.10) per share. The consensus mark for the same is pegged at $1.63 per share, suggesting a decline of 18.9% year over year.
<h2>Zacks Rank and Valuation</h2>
ADI shares currently have a stretched valuation, as suggested by a Value Score of D.
Analog Devices stock is trading with a forward 12-month Price/Sales of 10.86X compared with the industry&#39;s 7.78X.
ADI currently carries a Zacks Rank #3 (Hold), implying that investors should wait for a favorable entry point.
<a href="https://www.zacks.com/stock/news/2338731/adi-partners-with-india-s-tata-group-how-should-you-play-the-stock?cid=CS-BENZ-FT-analyst_blog|company_news_tech_sector-2338731">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Macro Economic Events

News

Guidance

Economics

Analyst Ratings

Tech

Trading Ideas

ADI Partners With India's Tata Group: How Should You Play the Stock?

Investors with a lot of money to spend have taken a bearish stance on Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HOOD, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Robinhood Markets.
This isn't normal.
The overall sentiment of these big-money traders is split between 0% bullish and 100%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $859,484, and 3 are calls, for a total amount of $241,235.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $24.0 to $30.0 for Robinhood Markets during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Robinhood Markets stands at 18946.5, with a total volume reaching 4,903.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Robinhood Markets, situated within the strike price corridor from $24.0 to $30.0, throughout the last 30 days.
<h3>Robinhood Markets 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726850879_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.2</td>
<td>$10.1</td>
<td>$10.2</td>
<td>$30.00</td>
<td>$305.0K</td>
<td>1.4K</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.2</td>
<td>$10.1</td>
<td>$10.2</td>
<td>$30.00</td>
<td>$174.4K</td>
<td>1.4K</td>
<td style="text-align: right;">771</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.15</td>
<td>$10.05</td>
<td>$10.15</td>
<td>$30.00</td>
<td>$173.5K</td>
<td>1.4K</td>
<td style="text-align: right;">599</td>
</tr>
<tr>
<td>HOOD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.15</td>
<td>$10.05</td>
<td>$10.15</td>
<td>$30.00</td>
<td>$126.8K</td>
<td>1.4K</td>
<td style="text-align: right;">426</td>
</tr>
<tr>
<td>HOOD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.09</td>
<td>$2.05</td>
<td>$2.05</td>
<td>$25.00</td>
<td>$102.5K</td>
<td>50.1K</td>
<td style="text-align: right;">634</td>
</tr>
</tbody>
</table>

<h3>About Robinhood Markets</h3>
Robinhood Markets Inc is creating a modern financial services platform. It designs its own products and services and delivers them through a single, app-based cloud platform supported by proprietary technology. Its vertically integrated platform has enabled the introduction of new products and services such as cryptocurrency trading, dividend reinvestment, fractional shares, recurring investments, and IPO Access. It earns transaction-based revenues from routing user orders for options, equities, and cryptocurrencies to market makers when a routed order is executed.
Following our analysis of the options activities associated with Robinhood Markets, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Robinhood Markets</h3>
<ul>
<li>Trading volume stands at 3,379,754, with HOOD's price down by -0.04%, positioned at $22.8.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 46 days.</li>
</ul>
<h3>Expert Opinions on Robinhood Markets</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $23.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Robinhood Markets, targeting a price of $27. 
&#x2A; An analyst from Barclays has elevated its stance to Equal-Weight, setting a new price target at $20. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Robinhood Markets options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

HOOD

Robinhood Markets Options Trading: A Deep Dive into Market Sentiment

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates XOMA Royalty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOMA#NASDAQ">XOMA</a>) with a Buy and maintains $117 price target.

Price Target

Reiteration

XOMA

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $117 Price Target

JP Morgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) shares are trading higher on Friday. The bank reportedly started internal testing of a new credit card product.
The move comes as a part of plans to expand its offerings to U.K. consumers, <a href="https://www.bloomberg.com/news/articles/2024-09-20/jpmorgan-begins-testing-uk-credit-cards-in-latest-overseas-foray?srnd=homepage-Americas&amp;sref=TBDibEcD" target="_blank" rel="noreferrer noopener">reported </a>Bloomberg. The bank&#8217;s senior executives are said to be testing the credit cards within their mobile apps.
A person familiar with the matter said to Bloomberg that the product has been under development for over a year.
The new credit card will be added alongside investment products from JPMorgan&#8217;s digital wealth manager, Nutmeg, on its U.K. retail app, the report noted.
Notably, Nutmeg is the U.K.&#8217;s first and now largest digital wealth manager and serves over 200,000 <a target="_blank" href="https://www.chase.co.uk/gb/en/product/invest-with-nutmeg/" rel="noreferrer noopener">customers</a>, per the company&#8217;s website.
In July, the bank&nbsp;warned its 86 million customers to prepare for potential <a target="_blank" href="https://www.benzinga.com/government/24/07/39645336/largest-consumer-bank-chase-hints-increased-cost-to-consumers-for-everyday-banking-services" rel="noreferrer noopener">new charges on their bank accounts</a>.
This week, as per a report, JPMorgan is reportedly in talks with Apple about taking over its credit card program. The discussions began earlier this year <a target="_blank" href="https://www.benzinga.com/news/24/09/40907844/jpmorgan-in-talks-to-take-over-apple-credit-card-what-investors-need-to-know" rel="noreferrer noopener">and have advanced in recent weeks</a>.
Notably, Goldman Sachs is the current card issuer, but Apple and Goldman decided to part ways last year in their partnership, which included credit cards and savings accounts.
Investors can gain access to the stock via&nbsp;iShares U.S. Financial Services ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>) and&nbsp;SPDR Select Sector Fund – Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>).
Price Action: JPM shares are down 0.04% at $210.40 at the last check Friday.
Image via Shutterstock

Equities

Media

AAPL

iShares Trust Dow Jones US Financial Services Index Fund

JP Morgan Targets UK With Fresh Credit Card Offering: Report

Telsey Advisory Group analyst Dana Telsey maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and raises the price target from $195 to $207.

Telsey Advisory Group Maintains Outperform on Ralph Lauren, Raises Price Target to $207

WIIM

SKYE

Skye Bioscience shares are trading lower amid sympathy with Novo Nordisk after the company reported results from its Phase2a trial of Monlunabant in obesity.

Nintendo ADR (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>) and The Pokémon Company have filed a patent infringement lawsuit against Palworld developer Pocketpair, a case that could have significant ramifications for the <a href="https://www.benzinga.com/general/gaming/24/09/40859915/palworld-going-free-to-play-developer-weighs-bold-yet-difficult-move">indie game studio. </a>
<h3 class="wp-block-heading">The Patent At The Heart Of The Case</h3>
According to Kiyoshi Kurihara, a Japanese patent attorney, the patent in question revolves around the game's monster-catching mechanic. 
See Also: <a href="https://www.benzinga.com/markets/asia/24/09/40945563/pok-mon-with-guns-nintendo-files-lawsuit-against-palworld-developer-over-alleged-patent-violations">&#8216;Pokémon With Guns&#8217;: Nintendo Files Lawsuit Against Palworld Developer Over Alleged Patent Violations</a>
Speaking to Yahoo Japan (<a href="https://automaton-media.com/en/news/whats-the-killer-patent-nintendo-is-suing-palworld-for-japanese-patent-attorney-offers-in-depth-analysis/">translated</a> by Automaton), Kurihara pointed to a "killer patent" that may be difficult to avoid for any game attempting to mirror the gameplay of Pokémon. 
The divisional patent (Patent No. 7545191) describes a process in which the player aims a capture item at a character on the field, releases it based on their input, and determines if the capture succeeds, causing the monster to become the player's property.
&#8220;It seems like it would be hard to avoid if you want to make a Pokémon-like game, and it's easy to infringe if you're not careful,&#8221; Kurihara explained.
Since the indie game's release, people have compared Palworld's "Pals" to Pokémon, but the lawsuit focuses on patents rather than copyright infringement.
<h3 class="wp-block-heading">A Legal Strategy In Motion</h3>
Kurihara suspects Nintendo strategically planned the timing of its lawsuit. Authorities approved the four divisional patents in August, months after Palworld&#8217;s January release.
This delay might explain why Nintendo waited to announce its lawsuit, giving it the legal grounds to pursue Pocketpair after solidifying the patent claims.
The lawsuit&#8217;s impact on Palworld&#8217;s availability on platforms like Steam and Xbox remains uncertain. Nintendo's patents focus on the catching mechanics central to Pokémon. This could compel Pocketpair to alter its game or even remove key features.
<h3 class="wp-block-heading">What's Next For Palworld?</h3>
At its peak, Palworld shattered concurrent player records and saw massive sales. It reportedly earned so much that Pocketpair struggled to manage the influx of profits.
The developer moved quickly to capitalize on this success. It even formed a new company, Palworld Entertainment, in partnership with Sony Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) to further develop the brand.
Speculation is already swirling that Palworld will be making its way to PlayStation. Rumors suggest an announcement is imminent at the Tokyo Game Show, set to run from Sept. 26-29.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/09/40859915/palworld-going-free-to-play-developer-weighs-bold-yet-difficult-move">Palworld Going Free-To-Play? Developer Weighs Bold, Yet &#8216;Difficult&#8217; Move</a></li>
</ul>
Image courtesy of Pocketpair.

Gaming

Legal

General

NTDOY

Sony Group Corporation American Depositary Shares

SONY

Nintendo's 'Killer Patent' Could Crush Palworld's Monster-Catching Gameplay, Expert Warns

Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and maintains $85 price target.

APLS

Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target

Needham analyst Mike Matson reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Hold.

MASI

Needham Reiterates Hold on Masimo

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 0.2% on Friday.
The Dow traded up 0.09% to 42,064.34 while the NASDAQ fell 0.25% to 17,969.11. The S&amp;P 500 also fell, dropping, 0.22% to 5,701.29.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40956889/jim-cramer-viking-therapeutics-has-many-ships-coming-in">Jim Cramer: Viking Therapeutics Has &#8216;Many Ships Coming In&#8217;</a>
Leading and Lagging Sectors Utilities shares jumped by 1.6% on Friday.
In trading on Friday, industrials shares fell by 1%.
Top Headline
Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported better-than-expected financial results for the third quarter on Thursday.
The company said it sees fourth-quarter new orders in a range of 19,000 to 19,300 and deliveries between 22,500 and 23,000. The company expects the average sales price to be approximately $425,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Banzai International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) shares shot up 131% to $6.62. Banzai International recently announced a 1-for-50 reverse stock split.</li>
<li>Shares of Battalion Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BATL#NYSE">BATL</a>) got a boost, surging 120% to $6.48 after the company announced it has amended its merger agreement with Fury Resources for the acquisition of all outstanding shares of Battalion at $7.00 per share in cash.</li>
<li>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) shares were also up, gaining 13% to $235.54 after the company announced it signed a 20-year power purchase agreement with Microsoft that will help launch the Crance Clean Energy Center and restart Three Mile Island Unit 1.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares dropped 59% to $21.12. RBC Capital analyst Brian Abrahams reiterated Corbus Pharmaceuticals with an Outperform rating and maintained the price target of $82.</li>
<li>Shares of Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) were down 19% to $22.79 after the company announced a $150 million private placement of 7.50 million shares.</li>
<li>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) was down, falling 15% to $254.45 as the company reported weaker-than-expected results for the first quarter of fiscal 2025 and lowered its full-year guidance.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $72.03 while gold traded up 1.3% at $2,649.40.
Silver traded up 0.1% to $31.455 on Friday, while copper fell 0.4% to $4.33.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 1.34%, Germany's DAX declined 1.43% and France's CAC 40 fell 1.38%. Spain's IBEX 35 Index slipped 0.03%, while London's FTSE 100 fell 1.09%.
Spain&#8217;s trade deficit narrowed to EUR 3.2 billion in July from EUR 4.9 billion in the year-ago month. The manufacturing climate indicator in France slipped to 98.6 in September from 98.9 in the prior month.
Retail sales in the UK rose 1% month-over-month in August compared to revised 0.7% gain in July. Producer prices in Germany fell by 0.8% year-over-year in August.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 1.53%, Hong Kong's Hang Seng Index surging 1.36%, China's Shanghai Composite Index gaining 0.03% and India's BSE Sensex gaining 1.63%.
Foreign exchange reserves held by the Reserve Bank of India climbed to $689.5 billion as of Sept. 13. The annual inflation rate in Hong Kong came in flat at 2.5% in August, while Hong Kong&#8217;s current account surplus increased to HKD 101.03 billion in the second quarter from HKD 50.71 billion in the year-ago period. The Bank of Japan kept its key short-term interest rate unchanged at around 0.25% during its recent meeting.
Economics
The Baker Hughes rig-count report for the latest week will be released at 1:00 p.m. ET. 
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40956962/top-3-financials-stocks-that-may-rocket-higher-this-quarter">Top 3 Financials Stocks That May Rocket Higher This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

BATL

BNZI

CRBP

Gold Gains Over 1%; Battalion Oil Shares Spike Higher

HC Wainwright &amp; Co. analyst Ed Arce reiterates Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) with a Buy and maintains $13 price target.

GNFT

HC Wainwright & Co. Reiterates Buy on Genfit, Maintains $13 Price Target

BMO Capital analyst Fadi Chamoun maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Outperform and lowers the price target from $280 to $275.

BMO Capital Maintains Outperform on Union Pacific, Lowers Price Target to $275

Shares of Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) experienced a severe drop on Friday, plummeting almost 60% from $52 to $21, as competitor Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) published trial results for monlunabant, a cannabinoid receptor 1 (CB1) inverse agonist. Novo Nordisk shares also traded down roughly 5.5%
Both companies are developing drugs that target the CB1 receptor, a critical part of the&nbsp;endocannabinoid system, which regulates appetite and metabolism. Corbus's experimental drug, CRB-913, belongs to the same class as monlunabant. 
Despite <a href="https://www.benzinga.com/insights/options/24/09/40940229/spotlight-on-novo-nordisk-analyzing-the-surge-in-options-activity">Novo Nordisk</a>'s announcement of results on weight-loss outcomes, investors appear to be concerned about the actual outcome of the trials.
Monlunabant, the drug tested by Novo Nordisk, acts on the same receptors as cannabis-related compounds.
It is a synthetic small molecule designed to block the CB1 receptor, which plays a key role in appetite regulation. The <a href="https://www.benzinga.com/markets/cannabis/22/07/28272841/the-endocannabinoid-system-101-the-basics-made-easy">endocannabinoid system</a>, which is naturally activated by cannabinoids from the cannabis plant, like THC, is the biological target of both Novo's monlunabant and Corbus's CRB-913.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/06/39363069/corbus-pharmaceuticals-board-member-to-sell-shares-in-planned-trading">Corbus Pharmaceuticals Board Member To Sell Shares In Planned Trading </a>
<h3 class="wp-block-heading">Bearish Reactions To Novo Nordisk's Trial Data</h3>
Novo Nordisk&#8217;s trial showed that monlunabant resulted in significant weight loss for participants, with those on a 10 mg dose losing an average of 7.1 kg compared to only 0.7 kg in the placebo group. 
However, the market's reaction was negative. Probable reasons for such market reactions are linked to:
<ul>
<li>Safety Concerns: While the trial showed significant weight loss, the adverse events, particularly neuropsychiatric side effects like anxiety, irritability and sleep disturbances, were dose-dependent and more frequent at higher doses. These side effects, even though mild to moderate, could raise concerns about the drug&#8217;s long-term safety and commercial viability, especially in the competitive obesity drug market​.</li>
<li>Limited Additional Benefits at Higher Doses: The trial indicated that&nbsp;limited additional weight loss&nbsp;was seen at higher doses of monlunabant, which might signal diminishing returns for increased dosages. This could raise questions about the drug&#8217;s scalability and effectiveness at higher or sustained dosages, casting doubt on its ability to compete with other obesity treatments that offer clearer dose-response benefits​.</li>
<li>Investor Expectations: Given Novo Nordisk's strong position in the obesity treatment market (notably with its blockbuster drug Wegovy), expectations for new pipeline drugs like monlunabant may have been exceedingly high.</li>
<li>Competition and Future Trials: While Novo has committed to advancing monlunabant into a larger phase 2b trial in 2025, this indicates that&nbsp;more work is needed to refine dosing&nbsp;and better understand the safety profile. The need for further trials may prolong investor uncertainty, particularly when competitors (like Corbus Pharmaceuticals) are also developing drugs targeting the same CB1 receptor pathway​</li>
</ul>
<h3 class="wp-block-heading">What This Means for Corbus Pharmaceuticals</h3>
For <a href="https://www.benzinga.com/markets/cannabis/24/06/39363069/corbus-pharmaceuticals-board-member-to-sell-shares-in-planned-trading">Corbus Pharmaceuticals</a>, Novo Nordisk's struggles present an even greater challenge. 
As CRB-913 is also a CB1 inverse agonist, the setbacks Novo faced may have deepened concerns about whether Corbus can develop a commercially viable product.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38803783/will-pharma-and-healthcare-have-competitive-edge-in-cannabis-post-rescheduling-data">Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In</a></li>
</ul>
Cover: Benzinga Pro

Cannabis

Health Care

Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week of Sept. 20:
Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>): The gold-mining company saw increased interest from readers this week on the heels of a 50 basis point cut to interest rates by the Federal Reserve, which saw gold prices rise. The interest also comes after Barrick Gold CEO Mark Bristow spoke at the Gold Forum Americas earlier this week and<a href="https://www.benzinga.com/news/24/09/40915786/barrick-forecasts-strong-organic-growth-by-2030-ceo-bristow-touts-undervaluation"> said the company expects </a>30% growth in gold-equivalent ounces by the end of the decade from its existing assets. 
Bristow's comments emphasized the company's current mines and those in development, as the industry experiences a surge in merger and acquisition activity. The CEO also highlighted how the company is expanding its copper portfolio, which could be something exciting to watch for investors.
Barrick shares were down 2% over the last five trading days, as seen on the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below. The stock is up 14% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png" alt="" class="wp-image-558808" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121633/Screenshot-183-768x371.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Galmed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>): The biopharmaceutical company <a href="https://www.benzinga.com/news/24/09/40941193/galmed-pharmaceuticals-stock-is-soaring-thursday-heres-why">saw shares soar </a>during the week after an announcement on drug development activities. Galmed plans to add drug developments that target cardiac fibrosis and colorectal and hepatic cancers. The company will release data from the studies during the fourth quarter.
"The conditions Galmed plans to focus upon in the coming years are major public health problems impacting millions of people worldwide and posing huge financial burden on health providers," Galmed CEO Allen Baharaff said.
Large interest in Galmed saw shares halted several times during the trading week. Helping with volatility in the biopharmaceutical company is the low-float of the stock with around 625,000 shares available according to Benzinga Pro. Low-float stocks can often see high volatility on company announcements.
The stock was up 160% over the last five days and up nearly 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png" alt="" class="wp-image-558810" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121656/Screenshot-184-768x388.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Read Also:&nbsp;<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40691773/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-august-2024-where-do-tesla-n" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?</a>
ServiceNow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>): The software company is seeing a large increase in interest from readers ahead of its third-quarter financial results. Analysts expect the company to report revenue of $2.74 billion, up from $2.29 billion in last year's third quarter.
The company has beaten analyst revenue estimates in six straight quarters. Analysts expect the company to report earnings per share of $3.46, up from $2.92 in last year's third quarter. ServiceNow has beaten earnings estimates from analysts in more than 20 straight quarters.
The company's earnings report will show investors and analysts whether revenue growth and AI platform demand are continuing to strengthen. The company saw subscription revenue up 23% year-over-year in <a href="https://www.benzinga.com/news/earnings/24/07/39944577/servicenow-q2-earnings-revenue-beat-eps-beat-servicenow-intends-to-reinvent-every-workflow-in-every">the second quarter </a>and said it was helping meet demand from CEOs looking for new growth as ServiceNow reinvents "every workflow, in every company, in every industry with GenAI at the core."
ServiceNow shares are up 4% over the last five days and up 34% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="997" height="514" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png" alt="" class="wp-image-558811" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185.png 997w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121712/Screenshot-185-768x396.png 768w" sizes="(max-width: 997px) 100vw, 997px" /></a></figure>
Deutsche Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>): It's not every week that a bank stock makes its way on the Stock Whisper Index, but here we are. Deutsche Bank saw strong interest from readers, which could be due to bank stocks getting a lift after the <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">interest rate cut was announced.</a> 
The move could see lenders have their balance sheets strengthened going forward and see increased demand for loan activity. Deutsche Bank reports third-quarter financial results in October and could comment on demand and what the future looks like for the company and the sector.
Shares were up 5% over the last five days and 24% year-to-date.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png" alt="" class="wp-image-558812" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121726/Screenshot-186-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stryker Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>): The medical equipment company saw strong interest from readers during the week, which comes on the heels of acquisition announcements, new products <a href="https://www.benzinga.com/quote/SYK/analyst-ratings">and analyst notes</a>. 
The company recently unveiled new foot and ankle solutions that can help restore limb length. Stryker closed its acquisition of privately held care.ai, a company helping with AI-assisted virtual care workflows and smart room technology. The company said the acquisition will help accelerate its digital vision and could expand its healthcare IT business. 
On Friday, Stryker closed its acquisition of NICO Corporation, a company with a surgery method for tumor and intracerebral hemorrhage procedures. Stryker also announced an acquisition of pain management company Vertos Medical in August. Together, the acquisitions and new products could have investors excited about the company's future and its potential diversification efforts.
Piper Sandler recently maintained an Overweight rating and a $380 price target on the stock. Wolfe Research initiated coverage with an Outperform rating and a $405 price target.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png" alt="" class="wp-image-558813" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20121742/Screenshot-187-768x387.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40420145/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 16</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 23</a></li>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">August 30</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40752686/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">September 6</a></li>
<li><a href="https://www.benzinga.com/top-stories/24/09/40855829/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">September 13 </a></li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40838414/gold-miners-eye-best-1-day-rally-in-6-months-as-gold-hits-fresh-record-highs-todays-environment-">Gold Miners Eye Best 1-Day Rally In 6 Months As Gold Hits Fresh Record Highs: &#8216;Today&#8217;s Environment Closely Resembles The 1970s&#8217;</a></li>
</ul>
Photo: Benzinga

Exclusives

GLMD

GOLD

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

<a href="https://deadline.com/2024/09/amazon-head-of-docuseries-alysia-russo-joins-netflix-1236094996/" title="https://deadline.com/2024/09/amazon-head-of-docuseries-alysia-russo-joins-netflix-1236094996/">https://deadline.com/2024/09/amazon-head-of-docuseries-alysia-russo-joins-netflix-1236094996/</a>

AMZN

NFLX

'Amazon's Head Of Docuseries Alysia Russo Leaves, Joins Netflix' - Deadline

Cantor Fitzgerald analyst Kristen Kluska reiterates Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) with a Overweight and maintains $14 price target.

Cantor Fitzgerald Reiterates Overweight on Skye Bioscience, Maintains $14 Price Target

ZVRA

Trading Halt: Halt status updated at 12:35:00 PM ET: Quotation Resumption: News and Resumption Times

BMO Capital analyst Fadi Chamoun maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Market Perform and lowers the price target from $325 to $300.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Hanstone Gold

Hanstone Gold (HANCF) Forecast

Hanstone Gold (OTC:HANCF) Stock, Quote.Headers.trade-ideas